1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Hypertension Drugs Market 2014-2018

Global Hypertension Drugs Market 2014-2018

  • April 2014
  • -
  • Infiniti Research Limited
  • -
  • 65 pages

About Hypertension Drugs

Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary.
TechNavio's analysts forecast the Global Hypertension Drugs market will grow at a CAGR of 1.2 percent over the period 2013-2018.

Covered in this Report

The Global Hypertension Drugs market can be categorized into eight segments: Diuretics, ACE Inhibitors, ARBs, CCB, Beta Blockers, Alpha Blockers, Vasodilators, and Renin Inhibitors. To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension.
TechNavio's report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

• Americas
Key Vendors
• Actelion Ltd.
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Novartis AG
• Pfizer Inc.
• Sanofi SA

Other Prominent Vendors

• Bayer AG
• Daiichi Sankyo Co. Ltd.
• Forest Laboratories Inc.
• Merck & Co. Inc.
• Takeda Pharmaceutical Co. Ltd.
• United Therapeutics Corp.
• Valeant Pharmaceuticals International Inc.
Key Market Driver
• Increase in Aging Population.
• For a full, detailed list, view our report.
Key Market Challenge
• Increasing Number of Patent Expirations.
• For a full, detailed list, view our report.
Key Market Trend
• Increasing Focus on Combination Therapies.
• For a full, detailed list, view our report.

Key Questions Answered in this Report

• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Global Hypertension Drugs Market 2014-2018
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Rate of Incidence and Prevalence
07.1.1 Americas
07.1.2 The APAC Region
07.1.3 Europe
08. Late Stage Pipeline Snapshot
09. Market Segmentation by Mechanism of Action
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Actelion Ltd.
19.1.1 Business Overview
19.1.2 Key Information
19.1.3 SWOT Analysis
19.2 AstraZeneca plc
19.2.1 Business Overview
19.2.2 Key Information
19.2.3 SWOT Analysis
19.3 Boehringer Ingelheim GmbH
19.3.1 Business Overview
19.3.2 Business Segmentation
19.3.3 Key Information
19.3.4 SWOT Analysis
19.4 Novartis AG
19.4.1 Business Overview
19.4.2 Business Segmentation
19.4.3 Key Information
19.4.4 SWOT Analysis
19.5 Pfizer Inc.
19.5.1 Business Overview
19.5.2 Business Segmentation
19.5.3 Key Information
19.5.4 SWOT Analysis
19.6 Sanofi SA
19.6.1 Business Overview
19.6.2 Business Segmentation
19.6.3 Key Information
19.6.4 SWOT Analysis
20. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Hypertension Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Global Hypertension Drugs Market Segmentation by Mechanism of Action
Exhibit 4: Global Hypertension Drugs Market 2013
Exhibit 5: Global Hypertension Drugs Market by Geographical Segmentation 2013
Exhibit 6: Global Hypertension Drugs Market by Vendor Segmentation 2013
Exhibit 7: Business Segmentation of Boehringer Ingelheim GmbH
Exhibit 8: Business Segmentation of Novartis AG
Exhibit 9: Business Segmentation of Pfizer Inc.
Exhibit 10: Business Segmentation of Sanofi SA

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.